Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Summary
A multi-center, prospective, open-label, randomized controlled study of efficacy and safety of Iguratimod in patients with Primary Sjögren's syndrome
Official title: The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome: a Multi-center, Prospective, Open Study
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
78
Start Date
2022-01-14
Completion Date
2025-07
Last Updated
2024-10-16
Healthy Volunteers
No
Conditions
Interventions
Iguratimod Tablets
Participants are treated with Iguratimod Tablets 25 mg Twice a day for 24 weeks.
Hydroxychloroquine Sulfate Tablets
Participants are treated with Hydroxychloroquine Sulfate Tablets 200 mg Twice a day for 24 weeks.
Locations (1)
Second affiliated hospital of zhejiang university,school of medical
Hangzhou, Zhejiang, China